What is Microvi Biotech?
Microvi Biotech operates at the intersection of biotechnology and environmental engineering, specializing in advanced filtration solutions designed to mitigate nitrate contamination in drinking water. The company provides a robust suite of services that extend beyond hardware, encompassing comprehensive case studies and empirical research that validate the efficacy of their biological treatment processes. As a leader in the clean water space, Microvi Biotech serves municipal and industrial clients, positioning itself as a vital player in the global effort to ensure sustainable access to potable water through innovative, low-energy, and high-efficiency filtration systems.
How much funding has Microvi Biotech raised?
Microvi Biotech has raised a total of $1.4M across 3 funding rounds:
Series A
$1M
Debt
$150K
Debt
$217K
Series A (2009): $1M with participation from Perry Solomon
Debt (2020): $150K led by PPP
Debt (2021): $217K supported by PPP
Key Investors in Microvi Biotech
Perry Solomon
An experienced individual investor with a focus on early-stage biotechnology and environmental technology ventures.
PPP
Public-Private Partnership
What's next for Microvi Biotech?
With the recent influx of capital, Microvi Biotech is poised to accelerate its research and development initiatives, focusing on the optimization of its nitrate removal platforms. The company is expected to expand its footprint in the enterprise water treatment market, leveraging its proven track record to secure larger municipal contracts. Strategic priorities likely include the scaling of manufacturing capabilities and the enhancement of its research division to address emerging contaminants. As the firm transitions into this next phase of growth, the focus remains on maintaining its competitive edge in the water technology sector while driving long-term value for stakeholders through sustainable, scalable infrastructure solutions.
See full Microvi Biotech company page
